Company EBITDA for fiscal year 2024 at EUR –0.85 million; postponement of publication of consolidated financial statements

On November 18, 2024, aap Implantate AG (“Company”) announced in an ad hoc announcement that EBITDA for the fiscal year 2024 was expected to be between EUR -0.5 million and EUR 0.5 million.

Contrary to the raised forecast, the Company's EBITDA for the 2024 fiscal year will amount to EUR -0.85 million. The deviation is mainly due to one-time charges that had to be recognized in the financial statements for the period in which they were incurred. EBITDA adjusted for one-time effects (recurring EBITDA) will amount to EUR -0.2 million and will be within the forecast range.

However, on Monday, June 30, 2025, the company will publish preliminary, unaudited financial information for the Group for the 2024 fiscal year in addition to the publication of the audited annual financial statements (individual financial statements). Irrespective of this, the publication of the audited consolidated financial statements will be postponed to July 2025. This is to allow sufficient time for the completion of the audit process, including ESEF tagging.

Contact:
If you have any questions, please contact:

aap Implantate AG; R. Di Girolamo; Chairman of the Management Board / CEO; Lorenzweg 5;
D-12099 Berlin, Tel.: +49/30/750 19 - 170; Fax: +49/30/750 19 - 290; r.digirolamo@aap.de